Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2024 - 2025)

Zhengye Biotechnology Holding has reported Accumulated Expenses over the past 2 years, most recently at $529000.0 for Q2 2025.

Quarterly Accumulated Expenses changed N/A to $529000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $529000.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $352000.0 for FY2024, N/A changed from the prior year.
Accumulated Expenses was $529000.0 for Q2 2025 at Zhengye Biotechnology Holding, up from $357923.6 in the prior quarter.
Over five years, Accumulated Expenses peaked at $529000.0 in Q2 2025 and troughed at $357923.6 in Q4 2024.